Indivior Pharmaceuticals (INDV) Research & Development (2024 - 2026)

Indivior Pharmaceuticals has reported Research & Development for 3 years, with the latest figure at $12.0 million in Q2 2026.

• On a quarterly basis, Research & Development fell 42.86% year-over-year to $12.0 million in Q2 2026; TTM through Jun 2026 was $82.0 million, a 14.58% decrease from a year earlier, with the FY2025 full-year figure at $97.0 million, down 9.35% from the prior year.
• Research & Development was $12.0 million for Q2 2026 at Indivior Pharmaceuticals, down from $16.0 million in the prior quarter.
• The five-year high for Research & Development was $33.0 million in Q3 2025, with the low at $12.0 million in Q2 2026.
• Average Research & Development over 3 years is $23.2 million, with a median of $22.0 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Research & Development surged 50.0% in 2025, then sank 42.86% in 2026.
• Over 3 years, Research & Development stood at $31.0 million in 2024, then sank by 32.26% to $21.0 million in 2025, then plunged by 42.86% to $12.0 million in 2026.
• The last three Research & Development figures came in at $12.0 million (Q2 2026), $16.0 million (Q1 2026), and $21.0 million (Q4 2025), per Business Quant data.